Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John MacDonald

Optometrist Monument, CO Doctor of Optometry

NPI 1912312943 CMS profile 816166

1860 Woodmoor Dr Ste 103, Monument, CO 80132

Open in the dashboard

General payments

$3,812

171 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John MacDonald of Monument, CO is reported in the CMS Open Payments database as having received $3,812 across 171 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $658 25
2024 General $495 18
2023 General $573 23
2022 General $881 33
2021 General $480 30
2020 General $338 19
2019 General $387 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John MacDonald
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to John MacDonald were reported at $658. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year John MacDonald Optometrist median Middle half National median
2019 $387 $159 $67–$371 $163
2020 $338 $72 $29–$165 $114
2021 $480 $125 $46–$292 $132
2022 $881 $162 $66–$374 $149
2023 $573 $177 $72–$406 $160
2024 $495 $188 $77–$427 $164
2025 $658 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $953 39 payments
  2. Alcon Vision LLC $864 49 payments
  3. Bausch & Lomb Americas Inc. $499 21 payments
  4. Johnson & Johnson Vision Care, Inc. $412 22 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $339 17 payments
  6. Sight Sciences, Inc. $144 1 payment
  7. Optos, Inc. $121 2 payments
  8. LKC Technologies, Inc. $93 1 payment
  9. ABB Con-Cise Optical Group LLC $85 5 payments
  10. Glaukos Corporation $74 1 payment
  11. Other $229 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,666 168 payments
  2. Entertainment $121 2 payments
  3. Consulting Fee $25 1 payment
Products named General payments · program years 2019–2025
  1. MyDay Contact Lens $515 24 payments
  2. INFUSE $480 20 payments
  3. DAILIES $347 24 payments
  4. Acuvue $330 18 payments
  5. Precision 1 $318 15 payments
  6. MiSight Contact Lens $236 4 payments
  7. BTOD $204 9 payments
  8. Clariti Contact Lens $202 11 payments
  9. ULTRA $198 11 payments
  10. BIOTRUE ONE DAY $153 7 payments
  11. Other $1,507 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

96

Median for Optometry: 120

Drug cost

$5,905

Median for Optometry: $8,864

Branded share of claims

13.5%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 13 $4,923
Prednisolone Acetate Generic 26 $698
Timolol Maleate Generic 17 $160
Latanoprost Generic 40 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$25,122

Medicare's payments for the services billed

Medicare patients

226

Average age 76

Services billed

350

130 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 43%
Diabetes 18%
Ischemic heart disease 16%
Chronic kidney disease 16%
Cancer 16%
Osteoporosis 15%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record